Peptide research & education — evidence-based compound guides

Medicare GLP-1 Bridge: $50/Month Weight Loss Drugs Starting July 2026

CMS announced the Medicare GLP-1 Bridge — a demonstration program offering eligible Medicare beneficiaries access to FDA-approved weight loss drugs for $50 per month starting July 1, 2026. Here is everything you need to know.

FDA Proposes Permanent Ban on Compounded Semaglutide and Tirzepatide

On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, effectively ending large-scale compounding of GLP-1 drugs. Comments are due June 29.

Inside the FDA Peptide Advisory Committee: What to Expect at the July 23–24 PCAC Meeting

The FDA’s Pharmacy Compounding Advisory Committee meets July 23–24 to vote on whether BPC-157, TB-500, Semax, Epitalon, MOTS-c, KPV, and DSIP should return to the compounding list. With 6 of 10 seats vacant and allegations of committee stacking, the outcome could reshape peptide access.

Foundayo (Orforglipron) FDA Approved: The First GLP-1 Pill You Can Take Any Time of Day

On April 1, 2026, the FDA approved Foundayo (orforglipron) — Eli Lilly's once-daily oral GLP-1 receptor agonist for weight loss. Unlike existing oral semaglutide, Foundayo can be taken any time of day without food or water restrictions, starting at $149/month.

FDA Removes 12 Peptides from Category 2: BPC-157, TB-500, Semax, and More No Longer Flagged as Safety Risks

On April 15, 2026, the FDA announced the removal of 12 peptide bulk drug substances from Category 2 — the list reserved for compounds with significant safety concerns. BPC-157, TB-500, Semax, MOTS-c, GHK-Cu (injectable), and seven others are affected. Here is what it means.

Stanford Discovers "Natural Ozempic" Peptide That Cuts Appetite 50% Without GI Side Effects

Stanford researchers used an AI tool called Peptide Predictor to scan all 20,000 human protein-coding genes and discovered BRP — a naturally occurring 12-amino-acid peptide that reduced food intake by 50% in mice and minipigs without the GI side effects of semaglutide. The study was published in Nature.

Semaglutide Fails Alzheimer's Trial: What the EVOKE Results Mean for GLP-1 Brain Claims

The largest clinical trial of semaglutide for Alzheimer's disease — the EVOKE program, enrolling 3,808 patients across 566 sites in 40 countries — failed to slow cognitive decline. But the biomarker data tells a more nuanced story, and the Parkinson's evidence remains stronger.

Tirzepatide for Weight Loss: What the Clinical Trials Actually Show

Tirzepatide delivered 20.2% body weight reduction in the SURMOUNT-5 head-to-head trial against semaglutide — the largest weight loss ever recorded for a GLP-1 class drug. This guide covers every major trial, the dosing escalation schedule, side effects, cost, and who should consider it.

Peptides for Women: Safety, Benefits, and What’s Different

Women metabolize peptides differently than men — hormonal cycles, body composition, and reproductive considerations all matter. This guide covers what the research actually shows about peptides in women, from GLP-1 agonists and fertility to PT-141 and growth hormone secretagogues.

What Are Peptides? A Science-Based Introduction

Peptides for Weight Loss: What the Research Shows

FDA Regulation of Peptides: What You Need to Know

Understanding Our Evidence Ratings

Growth Hormone Secretagogues Explained

GLP-1 Receptor Agonists: From Semaglutide to Retatrutide

How to Reconstitute Peptides: Step-by-Step

Peptide Storage & Handling Best Practices

How to Read Peptide Research Papers

Peptide Therapy: What You Need to Know Before Starting

Peptides for Muscle Growth: What the Research Actually Shows

Are Peptides Safe? What the Evidence Shows

Peptide Injection Sites: Subcutaneous vs Intramuscular Guide

Peptide Half-Life Reference: Dosing Frequency & Duration

Peptide Needle & Syringe Guide: Gauge, Length, and Sizing

Peptide Dosing Timing: When to Inject and Why It Matters